

VINEET LABORATORIES LIMITED
CIN:L24304TG2016PLC112888

SY. No. 11/A3, Eshwaramma Nilayam, Saheb Nagar, Kurdu Vill, Chintal Kunta, LB Nagar, Hyderabad, Telangana-500074, India.

Statement of Unaudited Financial Results for the quarter and half year ended 30 September 2023

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

S No	Particulars	Quarter ended			Half year ended		Year ended
		Quarter ended 30 September 2023	Quarter ended 30 June 2023	Quarter ended 30 September 2022	Half year ended 30 September 2023	Half year ended 30 September 2022	Year ended 31 March 2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	a) Net Sales/income from operations	4,337.27	3,752.30	3,950.55	8,089.57	8,832.72	21,229.33
II	b) Other income	1.44	2.55	0.28	3.99	8.74	12.30
III	Total Income (I + II)	4,338.71	3,754.85	3,950.83	8,093.56	8,841.46	21,241.63
VI	Expenses						
	a) Cost of material consumed	3,174.85	3,030.31	3,703.80	6,205.16	7,515.34	16,809.76
	b) Changes in inventories of finished goods, work-in progress and stock-in-trade(increase)/decrease	(131.37)	48.23	(129.56)	(83.14)	(293.36)	423.03
	c) Employee benefits expense	139.65	140.24	124.30	279.89	245.61	600.29
	d) Finance costs	102.46	95.88	61.37	198.34	197.97	338.02
	e) Depreciation and amortisation expenses	61.20	60.86	70.46	122.06	124.68	237.26
	f) Other expenses	737.49	507.55	652.96	1,245.04	1,374.87	2,630.28
	Total expenses	4,084.27	3,883.07	4,483.33	7,967.34	9,165.11	21,038.64
V	Profit/(loss) before exceptional items and tax (III - IV)	254.44	(128.22)	(532.50)	126.22	(323.65)	202.99
VI	Exceptional items	-	-	-	-	-	-
VII	Profit/(loss) before Tax (V - VI)	254.44	(128.22)	(532.50)	126.22	(323.65)	202.99
VIII	Tax expense :						
	a. Current tax	10.48	-	(63.10)	10.48	-	56.02
	b. Deferred tax	2.06	(3.23)	0.44	(1.17)	45.14	21.72
IX	Profit/(loss) for the period (VII-VIII)	241.90	(125.00)	(469.84)	116.91	(368.79)	125.25
X	Other comprehensive income(OCI)						
	A.						
	(i) Items that will not be reclassified subsequently to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	-	-	-	-	-	-
	B.						
	(i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	17.99
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	(4.53)
	Total other comprehensive income	-	-	-	-	-	13.46
XI	Total comprehensive income for the Period (IX+X)	241.90	(125.00)	(469.84)	116.91	(368.79)	138.71
XII	Paid-up Equity Share capital (Face Value of Rs. 10/- per share)	921.90	921.90	921.90	921.90	921.90	921.90
XIII	Other Equity	-	-	-	-	-	2,446.45
XIV	Earnings per equity share (of Rs. 10/- each) (not annualised for the quarters)						
	(i) Basic	2.62	(1.36)	(5.10)	1.27	(4.00)	1.36
	(ii) Diluted.	2.62	(1.36)	(5.10)	1.27	(4.00)	1.36

Notes

- The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules 2016.
- The above unaudited results have been reviewed by the Audit Committee of the board and approved by the Board of Directors of the Company at their meeting held on 10 November 2023.
- The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results and their report has been placed before the board at the said meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
- The company operates in one reportable business segment i.e. Active pharmaceuticals ingredient and intermediates. Hence segmental reporting as per Ind AS 108 is not applicable.
- The results for the quarter and half year ended 30 September 2023 are also available on website of BSE Limited, NSE Limited and on the Company's website.
- Figures for the previous periods have been rearranged/ reclassified wherever necessary to conform to the current period presentation.

Date: 10-11-2023
Place: Hyderabad.



For and on Behalf of Board of Directors

BH.Satyanarayana Raju
Wholtime Director
2697880

VINEET LABORATORIES LIMITED
CIN:L24304TG2016PLC112888

Regd Office : SY . No. 11/A3, Saheb nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana-500074, India.
Un-Audited Statement of Financial Position as at 30 September 2023

Amt in Rs.

	Particulars	Note No.	As at September 30, 2023	As at Mar 31, 2023
I	ASSETS			
1	Non-current assets			
	(a) Property, plant and equipment	2	26,16,09,289	26,64,56,619
	(i) Financial assets			
	(i) Investments	3	16,48,250	13,35,089
	(vi) other Financial assets	6	68,96,781	68,96,781
	(k) Other non-current asset	8	94,50,809	91,72,321
	Total non-current assets (A)		27,96,05,129	28,38,60,810
2	Current assets			
	(a) Inventories	9	43,52,22,875	46,17,37,737
	(b) Financial assets			
	(i) Trade receivables	4	46,61,14,032	35,16,30,947
	(ii) Cash and cash equivalents	10	62,14,090	63,07,376
	(iv) Bank Balances other than (iii) above		48,68,208	31,59,802
	(iv) other financial assets	6	7,031	2,95,940
	(d) Other current assets	11	2,78,53,808	5,14,99,247
	Total current assets (B)		94,02,80,044	87,46,31,049
	Total assets (A+B+C)		1,21,98,85,172	1,15,84,91,859
II	EQUITY AND LIABILITIES			
1	Equity			
	(a) Equity share capital	13	9,21,90,080	9,21,90,080
	(b) Other equity	14	25,63,34,895	24,46,44,324
	Total equity (A)		34,85,24,975	33,68,34,404
2	Liabilities			
(i)	Non-current liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	15	4,39,39,389	4,84,78,862
	(b) Long term provisions	18	75,44,587	75,44,588
	(c) Deferred tax Liabilities(Net)	7	2,04,19,113	2,05,35,970
	Total non-current liabilities (B)		7,19,03,089	7,65,59,420
(ii)	Current liabilities			
	(a) Financial liabilities			
	(i) Borrowings	15	36,22,55,687	26,24,09,318
	(ii) Trade payables	16		11,76,46,077
	(a) Total outstanding dues of micro and small enterprises		18,69,54,730	23,12,98,242
	(b) Total outstanding dues of creditors other than micro and small enterprises		23,05,98,692	
	(iii) Other financial liabilities	17	33,31,155	26,79,355
	(b) Short term provisions	18	34,03,390	34,03,390
	(c) Other current liabilities	19	85,29,730	12,32,62,585
	(d) Current Tax Laibilities (net)	7	43,83,729	43,99,069
	Total current liabilities (C)		79,94,57,113	74,50,98,036
	Total liabilities (D+B+C)		87,13,60,202	82,16,57,456
	Total equity and liabilities (A+D)		1,21,98,85,176	1,15,84,91,860

The notes are an integral part of the financial statements

For and on behalf of the Board of Directors
VINEET LABORATORIES LIMITED



Bh. Satyanarayana Raju
Wholesale Director
DIN:02697880

Place: Hyderabad
Date:10.11.2023

VINEET LABORATORIES LIMITED
CIN:L24304TG2016PLC112888

Regd Office : SY . No. 11/A3, Saheb nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana-500074, India.
Un-Audited Statement of Profit and Loss and Other Comprehensive Income for the Year ended 30 September 2023

Particulars	NoteNo.	For the period ended Sept 2023	For the year ended March 31, 2023
Continuing Operations			
I Revenue from operations	20	80,89,56,900	2,12,29,33,046
II Other income	21	3,99,198	12,30,137
III Total income		80,93,56,098	2,12,41,63,183
IV Expenses			
(a) Cost of material Consumed	23	62,05,15,862	1,68,09,76,077
(b) Purchase of Stock in Trade			
(c) Changes in stock of finished goods, work-in progress and stock-in-trade	24	(83,14,176)	4,23,03,019
(d) Employee benefits	25	2,79,88,546	6,00,29,343
(e) Finance cost	26	1,98,34,104	3,38,01,876
(f) Depreciation expense	27	1,22,05,764	2,37,26,002
(g) Other expenses	28	12,45,04,050	26,30,27,653
Total expenses (IV)		79,67,34,150	2,10,38,63,970
Profit/(loss) before Share of profit/(loss) of associates / joint ventures, exceptional items and tax (V - VI)		1,26,21,948	2,02,99,213
V		-	-
VI		-	-
VII Profit/(Loss) before exceptional items and tax		1,26,21,948	2,02,99,213
VIII Exceptional itmes		-	-
IX Profit before Tax		1,26,21,948	2,02,99,213
X Tax expense :			
a. Current tax		10,48,235	56,01,754
b. Deferred tax		(1,16,857)	21,72,005
Total			
XI Profit/(loss) for the year from continuing operations (XI-XII)		1,16,90,570	1,25,25,454
Discontinued Operations			
XII Profit/(loss) from discontinued operations		-	-
XIII Tax Expense of discontinued operations		-	-
XIV Profit/(loss) from discontinued operations (XIV +XV)		-	-
XV XVII Profit/(loss) for the year (XIII+XVI)		1,16,90,570	1,25,25,454
XVI Other comprehensive income(OCI)			
A (i) Items that will not be reclassified to profit or loss <i>Re-measurement gains/ (losses) on defined benefit plans</i>		-	17,98,982
<i>Income tax effect relating to above item</i>		-	(4,52,804)
B (i) Items that may be reclassified to profit or loss		-	-
(ii) Income tax on items that may be reclassified to profit or loss		-	-
Total other comprehensive income		-	13,46,178
XVII Total comprehensive income for the year (V+ VI)		1,16,90,570	1,38,71,632
XVIII Earning per equity share (for Continuing Opertations)			
(i) Basic		1.27	1.36
(ii) Diluted.		1.27	1.36
XIX Earnings per equity share (for discontinued operation):			
(i) Basic		0	0
(ii) Diluted.		0	0
XX Earnings per equity share (for Continued and discontinued operation):			
(i) Basic		1.27	1.36
(ii) Diluted.		1.27	1.36

The notes are an integral part of the financial statements



For and on behalf of the Board of Directors
VINEET LABORATORIES LIMITED

Bh. Satyanarayana Raju
Wholetime Director
DIN:02697880

Place: Hyderabad
Date:10.11.2023

VINEET LABORATORIES LIMITED
CIN:L24304TG2016PLC112888

Regd Office : SY . No. 11/A3, Saheb nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana-500074, India.

Un-Audited CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30th September 2023

Particulars	As at September 30, 2023	As at Mar 31, 2023
A. CASH FROM OPERATING ACTIVITIES		
Profit/(Loss) before tax and extraordinary items	1,26,21,948	2,02,99,213
Adjustment for:		
Income tax expense recognised in profit or loss		
Finance costs recognised in profit or loss	1,98,34,104	3,38,01,876
Interest income recognised in profit or loss	(21,233)	(12,30,137)
Fair Value Loss of Mutual Funds	-	-
Depreciation and amortisation of non-current assets	1,22,05,764	2,37,26,002
Net foreign exchange (gain)/loss	-	-
Other comprehensive income	-	(13,46,179)
Operating Profit before Working Capital Changes	4,46,40,583	7,52,50,776
Movement for Working Capital:		
(Increase)/ decrease in trade and other receivables	(11,44,83,085)	6,51,56,002
(Increase)/decrease in inventories	2,65,14,862	(3,85,41,032)
(Increase)/decrease in other assets	2,36,45,439	(3,01,30,329)
Decrease/(Increase) in Other non Current Assets	(2,78,488)	(6,80,37,385)
(Increase)/decrease in other financial assets	34,48,711	-
Increase/ (Decrease) in trade payables	6,86,09,103	4,10,41,639
Increase/(decrease) in provisions	(1)	1,94,25,527
(Decrease)/increase in other liabilities	(11,47,32,855)	(1,39,76,163)
Increase/(Decrease) in other financial Liabilities	6,51,800	-
(Decrease)/Increase in Other non Current Liabilities	-	7,25,569
Cash generated from operations	(6,19,83,931)	5,09,14,603
- Income taxes paid	(10,63,575)	(56,01,754)
Net Cash flow before extraordinary items	(6,30,47,506)	4,53,12,849
NET CASH FROM OPERATING ACTIVITIES	(6,30,47,506)	4,53,12,849
B. CASH FLOW FROM INVESTING ACTIVITIES:		
Purchase of Property Plat and Equipment	(73,58,433)	-
Payments to acquire financial assets	-	(3,73,44,275)
Interest received	21,233	16,23,520
Proceeds from Margin Money Deposits	(48,68,208)	-
Investment in Fixed Deposits	-	(10,67,471)
Investments in Mutual funds	(3,13,161)	-
NET CASH FROM INVESTING ACTIVITIES	(1,25,18,569)	(3,67,88,226)
C. CASH FLOW FROM FINANCING ACTIVITIES		
(Repayment)/ Proceeds of Long term borrowings	(53,68,583)	14,04,07,548
Proceeds from short term borrowings	10,06,75,479	-
Dividends paid	-	-
Interest paid	(1,98,34,104)	(3,38,01,876)
NET CASH FROM FINANCING ACTIVITIES	7,54,72,792	10,66,05,672
NET INCREASE IN CASH & CASH EQUIVALENTS	(93,283)	11,51,30,295
Cash and cash equivalents at the beginning of the year	63,07,376	75,09,156
Cash and cash equivalents at the end of the year as on 31.03.2023	62,14,093	12,26,39,451

For and on behalf of the Board of Directors
VINEET LABORATORIES LIMITED



Bh. Satyanarayana Raju
Wohletine Director
DIN:02697880

Place: Hyderabad
Date:10.11.2023



Limited Review Report on Unaudited financial results of M/s Vineet Laboratories Limited

Independent Auditor's Report on Quarterly and Year to Date Unaudited financial Results of M/s VINEET LABORATORIES LIMITED pursuant to regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015.

TO THE BOARD OF DIRECTORS OF Vineet Laboratories Limited

We have reviewed the accompanying unaudited financial results of **M/s Vineet Laboratories Limited**, for the quarter ended 30 September 2023 and for the period from 1 April 2023 to 30 September 2023. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with Standards on Auditing. Accordingly, we do not express an audit opinion on these financial results. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and that it contains any material misstatement.

Based on our review, nothing has come to our attention that causes us to believe that these financial statements do not give a true and fair view of the financial position of **M/s Vineet Laboratories Limited** as at 30 September 2023.

For NSVR & Associates LLP
Chartered Accountants
FRN: 008801S/S200060



V. G. Dhara
V Gangadhara Rao, N
Partner

M. No.219486
UDIN: 23219486BGQCY2236
Place: Hyderabad
Date: 10-11-2023.

NSVR & ASSOCIATES LLP